Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene

• Verfasst von: Rath, Michèlle Geneviève [VerfasserIn]
• Verfasst von: Fathali Zadeh, Farnoosh [VerfasserIn]
• Verfasst von: Langheinz, Anne [VerfasserIn]
• Verfasst von: Tchatchou, Sandrine [VerfasserIn]
• Verfasst von: Voigtländer, Theda [VerfasserIn]
• Verfasst von: Heil, Jörg [VerfasserIn]
• Verfasst von: Golatta, Michael [VerfasserIn]
• Verfasst von: Schott, Sarah [VerfasserIn]
• Verfasst von: Drasseck, Teresa [VerfasserIn]
• Verfasst von: Behnecke, Anne [VerfasserIn]
• Verfasst von: Burgemeister, Anna Lena [VerfasserIn]
• Verfasst von: Evers, Christina [VerfasserIn]
• Verfasst von: Bugert, Peter [VerfasserIn]
• Verfasst von: Junkermann, Hans [VerfasserIn]
• Verfasst von: Schneeweiss, Andreas [VerfasserIn]
• Verfasst von: Bartram, Claus R. [VerfasserIn]
• Verfasst von: Sohn, Christof [VerfasserIn]
• Verfasst von: Sutter, Christian [VerfasserIn]
• Verfasst von: Burwinkel, Barbara [VerfasserIn]
• Titel: Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene
• Verf.angabe: Michelle G. Rath, Farnoosh Fathali-Zadeh, Anne Langheinz, Sandrine Tchatchou, Theda Voigtländer, Jörg Heil, Michael Golatta, Sarah Schott, Teresa Drasseck, Anne Behnecke, Anna-Lena Burgemeister, Christina Evers, Peter Bugert, Hans Junkermann, Andreas Schneeweiss, Claus R. Bartram, Christof Sohn, Christian Sutter, Barbara Burwinkel
• E-Jahr: 2012
• Jahr: 8 January 2012
• Umfang: 10 S.
• Fussnoten: Gesehen am 05.04.2018
• Titel Quelle: Enthalten in: Breast cancer research and treatment
• Ort Quelle: Dordrecht [u.a.] : Springer Science + Business Media B.V., 1981
• Jahr Quelle: 2012
• Band/Heft Quelle: 133(2012), 2, Seite 725-734
• ISSN Quelle: 1573-7217
• DOI: doi:10.1007/s10549-011-1917-0
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1571752390

Abstract

In this study, we analyzed a “variant of uncertain significance” (VUS) located in exon 23 of the BRCA2 gene exhibited by six members of five distinct families with hereditary breast cancer (BC). The variant was identified by DNA sequencing, and cDNA analysis revealed its co-expression with wild-type mRNA. We analyzed co-occurrence with other pathological mutations in BRCA1/2, performed a case-control study, looked for evolutionary data and used in-silico analyses to predict its potential clinical significance. Sequencing revealed an in frame deletion of 126 nucleotides in exon 23, leading to a deletion of 42 amino acids (c.9203_9328del126, p.Pro2992_Thr3033del). All of the VUS-carriers suffered from either BC or ovarian/pancreatic cancer. No other definite pathologic mutation of BRCA genes was found in the five families. The identified deletion could not be observed in a control cohort of 2,652 healthy individuals, but in 5 out of 916 (0.5%) tested BC families without a bona fide pathogenic BRCA1/2 mutation (P = 0.0011). According to these results, the in frame deletion c.9203_9328del126 is a rare mutation strongly associated with familial BC. In summary, our investigations indicate that this BRCA2 deletion is pathogenic.